Clinical Trial Update: A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase I/II study evaluating Simmitinib or irinotecan liposomes in combination with DP303c for HER2-expressing gastric ade…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• DP303c (DP303c)
• Irinotecan Liposomes (irinotecan liposome)
• Simmitinib (simmitinib)

Snippet

Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd | Conditions: Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING